PURPOSE: The aim of this study was to assess the independent prognostic value of primary tumor mitotic rate compared with other clinical and pathologic features of stages I and II melanoma. METHODS: From the American Joint Committee on Cancer (AJCC) melanoma staging database, information was extracted for 13,296 patients with stages I and II disease who had mitotic rate data available. RESULTS: Survival times declined as mitotic rate increased. Ten-year survival ranged from 93% for patients whose tumors had 0 mitosis/mm(2) to 48% for those with ≥ 20/mm(2) (P < .001). Mean number of mitoses/mm(2) increased as the primary melanomas became thicker (1.0 for melanomas ≤ 1 mm, 3.5 for 1.01 to 2.0 mm, 7.3 for 3.01 to 4.0 mm, and 9.6 for > 8 mm). Ulceration was also associated with a higher mitotic rate; 59% of ulcerated melanomas had ≥ 5 mitoses/mm(2) compared with 16% of nonulcerated melanomas (P < .001). In a multivariate analysis of 10,233 patients, the independent predictive factors for survival in order of statistical significance were as follows: tumor thickness (χ(2) = 104.9; P < .001), mitotic rate (χ(2) = 67.0; P < .001), patient age (χ(2) = 48.2; P < .001), ulceration (χ(2) = 46.4; P < .001), anatomic site (χ(2) = 34.6; P < .001), and patient sex (χ(2) = 33.9; P < .001). Clark level of invasion was not an independent predictor of survival (χ(2) = 3.2; P = .37). CONCLUSION: A high mitotic rate in a primary melanoma is associated with a lower survival probability. Among the independent predictors of melanoma-specific survival, mitotic rate was the strongest prognostic factor after tumor thickness.
PURPOSE: The aim of this study was to assess the independent prognostic value of primary tumor mitotic rate compared with other clinical and pathologic features of stages I and II melanoma. METHODS: From the American Joint Committee on Cancer (AJCC) melanoma staging database, information was extracted for 13,296 patients with stages I and II disease who had mitotic rate data available. RESULTS: Survival times declined as mitotic rate increased. Ten-year survival ranged from 93% for patients whose tumors had 0 mitosis/mm(2) to 48% for those with ≥ 20/mm(2) (P < .001). Mean number of mitoses/mm(2) increased as the primary melanomas became thicker (1.0 for melanomas ≤ 1 mm, 3.5 for 1.01 to 2.0 mm, 7.3 for 3.01 to 4.0 mm, and 9.6 for > 8 mm). Ulceration was also associated with a higher mitotic rate; 59% of ulcerated melanomas had ≥ 5 mitoses/mm(2) compared with 16% of nonulcerated melanomas (P < .001). In a multivariate analysis of 10,233 patients, the independent predictive factors for survival in order of statistical significance were as follows: tumor thickness (χ(2) = 104.9; P < .001), mitotic rate (χ(2) = 67.0; P < .001), patient age (χ(2) = 48.2; P < .001), ulceration (χ(2) = 46.4; P < .001), anatomic site (χ(2) = 34.6; P < .001), and patient sex (χ(2) = 33.9; P < .001). Clark level of invasion was not an independent predictor of survival (χ(2) = 3.2; P = .37). CONCLUSION: A high mitotic rate in a primary melanoma is associated with a lower survival probability. Among the independent predictors of melanoma-specific survival, mitotic rate was the strongest prognostic factor after tumor thickness.
Authors: V J McGovern; M C Mihm; C Bailly; J C Booth; W H Clark; A J Cochran; E G Hardy; J D Hicks; A Levene; M G Lewis; J H Little; G W Milton Journal: Cancer Date: 1973-12 Impact factor: 6.860
Authors: P J Heenan; L R Matz; J B Blackwell; G R Kelsall; A Singh; R E ten Seldam; C D Holman Journal: Histopathology Date: 1984-09 Impact factor: 5.087
Authors: Susan B Kesmodel; Giorgos C Karakousis; Jeffrey D Botbyl; Robert J Canter; Robert T Lewis; Peter M Wahl; Kyla P Terhune; Abass Alavi; David E Elder; Michael E Ming; DuPont Guerry; Phyllis A Gimotty; Douglas L Fraker; Brian J Czerniecki; Francis R Spitz Journal: Ann Surg Oncol Date: 2005-04-19 Impact factor: 5.344
Authors: Phyllis A Gimotty; DuPont Guerry; Michael E Ming; Rosalie Elenitsas; Xiaowei Xu; Brian Czerniecki; Francis Spitz; Lynn Schuchter; David Elder Journal: J Clin Oncol Date: 2004-08-09 Impact factor: 44.544
Authors: K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan Journal: Ir J Med Sci Date: 2014-11-01 Impact factor: 1.568
Authors: Maxine C Dudek; Kaitlyn E Wong; Lotfi M Bassa; Maria Carmen Mora; Jennifer Ser-Dolansky; Jean M Henneberry; Giovanna M Crisi; Richard B Arenas; Sallie S Schneider Journal: Tumour Biol Date: 2015-07-10
Authors: Sumeet Thareja; Jonathan S Zager; Divya Sadhwani; Shalini Thareja; Ren Chen; Suroosh Marzban; Drazen M Jukic; Lewis F Glass; Jane Messina Journal: Am J Dermatopathol Date: 2014-01 Impact factor: 1.533
Authors: S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto Journal: Clin Transl Oncol Date: 2013-10-16 Impact factor: 3.405
Authors: Alexander H R Varey; Chris Goumas; Angela M Hong; Graham J Mann; Gerald B Fogarty; Jonathan R Stretch; Robyn P M Saw; Andrew J Spillane; Kerwin F Shannon; Kenneth J Lee; Michael J Quinn; John F Thompson; Richard A Scolyer Journal: Mod Pathol Date: 2017-07-21 Impact factor: 7.842